Development of a SARS Coronavirus Vaccine from Recombinant Spike Protein Plus Delta Inulin Adjuvant

Given periodic outbreaks of fatal human infections caused by coronaviruses, development of an optimal coronavirus vaccine platform capable of rapid production is an ongoing priority. This chapter describes the use of an insect cell expression system for rapid production of a recombinant vaccine agai...

Descripción completa

Detalles Bibliográficos
Autores principales: McPherson, Clifton, Chubet, Richard, Holtz, Kathy, Honda-Okubo, Yoshikazu, Barnard, Dale, Cox, Manon, Petrovsky, Nikolai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139448/
https://www.ncbi.nlm.nih.gov/pubmed/27076136
http://dx.doi.org/10.1007/978-1-4939-3387-7_14
_version_ 1783518768288235520
author McPherson, Clifton
Chubet, Richard
Holtz, Kathy
Honda-Okubo, Yoshikazu
Barnard, Dale
Cox, Manon
Petrovsky, Nikolai
author_facet McPherson, Clifton
Chubet, Richard
Holtz, Kathy
Honda-Okubo, Yoshikazu
Barnard, Dale
Cox, Manon
Petrovsky, Nikolai
author_sort McPherson, Clifton
collection PubMed
description Given periodic outbreaks of fatal human infections caused by coronaviruses, development of an optimal coronavirus vaccine platform capable of rapid production is an ongoing priority. This chapter describes the use of an insect cell expression system for rapid production of a recombinant vaccine against severe acute respiratory syndrome coronavirus (SARS). Detailed methods are presented for expression, purification, and release testing of SARS recombinant spike protein antigen, followed by adjuvant formulation and animal testing. The methods herein described for rapid development of a highly protective SARS vaccine are equally suited to rapid development of vaccines against other fatal human coronavirus infections, e.g., the MERS coronavirus.
format Online
Article
Text
id pubmed-7139448
institution National Center for Biotechnology Information
language English
publishDate 2015
record_format MEDLINE/PubMed
spelling pubmed-71394482020-04-08 Development of a SARS Coronavirus Vaccine from Recombinant Spike Protein Plus Delta Inulin Adjuvant McPherson, Clifton Chubet, Richard Holtz, Kathy Honda-Okubo, Yoshikazu Barnard, Dale Cox, Manon Petrovsky, Nikolai Vaccine Design Article Given periodic outbreaks of fatal human infections caused by coronaviruses, development of an optimal coronavirus vaccine platform capable of rapid production is an ongoing priority. This chapter describes the use of an insect cell expression system for rapid production of a recombinant vaccine against severe acute respiratory syndrome coronavirus (SARS). Detailed methods are presented for expression, purification, and release testing of SARS recombinant spike protein antigen, followed by adjuvant formulation and animal testing. The methods herein described for rapid development of a highly protective SARS vaccine are equally suited to rapid development of vaccines against other fatal human coronavirus infections, e.g., the MERS coronavirus. 2015-12-17 /pmc/articles/PMC7139448/ /pubmed/27076136 http://dx.doi.org/10.1007/978-1-4939-3387-7_14 Text en © Springer Science+Business Media New York 2016 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Article
McPherson, Clifton
Chubet, Richard
Holtz, Kathy
Honda-Okubo, Yoshikazu
Barnard, Dale
Cox, Manon
Petrovsky, Nikolai
Development of a SARS Coronavirus Vaccine from Recombinant Spike Protein Plus Delta Inulin Adjuvant
title Development of a SARS Coronavirus Vaccine from Recombinant Spike Protein Plus Delta Inulin Adjuvant
title_full Development of a SARS Coronavirus Vaccine from Recombinant Spike Protein Plus Delta Inulin Adjuvant
title_fullStr Development of a SARS Coronavirus Vaccine from Recombinant Spike Protein Plus Delta Inulin Adjuvant
title_full_unstemmed Development of a SARS Coronavirus Vaccine from Recombinant Spike Protein Plus Delta Inulin Adjuvant
title_short Development of a SARS Coronavirus Vaccine from Recombinant Spike Protein Plus Delta Inulin Adjuvant
title_sort development of a sars coronavirus vaccine from recombinant spike protein plus delta inulin adjuvant
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139448/
https://www.ncbi.nlm.nih.gov/pubmed/27076136
http://dx.doi.org/10.1007/978-1-4939-3387-7_14
work_keys_str_mv AT mcphersonclifton developmentofasarscoronavirusvaccinefromrecombinantspikeproteinplusdeltainulinadjuvant
AT chubetrichard developmentofasarscoronavirusvaccinefromrecombinantspikeproteinplusdeltainulinadjuvant
AT holtzkathy developmentofasarscoronavirusvaccinefromrecombinantspikeproteinplusdeltainulinadjuvant
AT hondaokuboyoshikazu developmentofasarscoronavirusvaccinefromrecombinantspikeproteinplusdeltainulinadjuvant
AT barnarddale developmentofasarscoronavirusvaccinefromrecombinantspikeproteinplusdeltainulinadjuvant
AT coxmanon developmentofasarscoronavirusvaccinefromrecombinantspikeproteinplusdeltainulinadjuvant
AT petrovskynikolai developmentofasarscoronavirusvaccinefromrecombinantspikeproteinplusdeltainulinadjuvant

Ejemplares similares